Efficacy of levocarnitine chloride for myocardial fatty acid metabolism in dialysis patients
Not Applicable
Recruiting
- Conditions
- Chronic renal failure
- Registration Number
- JPRN-UMIN000007650
- Lead Sponsor
- 1.Seseragi hospital 2.Department of Medicine & Biological Science Gunma University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
1.patients with a histry of oral levocarnitine chloride including carnitine supplements on the market 2.female patients who are pregnant, nursing or suspected of pregnancy 3.unsuitable patients
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1.Serum Asymmeteric dimethylarginen (ADMA) 2.Serum Fatty acid bindingprotein (FABP)3,4 and 5
- Secondary Outcome Measures
Name Time Method 1.Serum Acyl carnitine and Free carnitine 2.Plasma Brain natriuretic peptide 3.Serum Cardiac Troponin T 4.Echocardiography 5.Electrocardiogram 6.Cardiothoracic ratio in chest X ray photograph 7.Erithropoietic resistance index
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie levocarnitine chloride's impact on myocardial fatty acid oxidation in chronic renal failure patients undergoing dialysis?
How does levocarnitine chloride compare to standard carnitine supplementation in improving cardiac acyl-CoA metabolism for dialysis-dependent chronic kidney disease patients?
Which biomarkers, such as plasma acylcarnitine profiles or OCTN2 expression, predict response to levocarnitine chloride in dialysis patients with chronic renal failure?
What are the safety profiles and management strategies for cardiotoxicity or arrhythmias associated with levocarnitine chloride in end-stage renal disease patients on dialysis?
Are there synergistic effects of combining levocarnitine chloride with omega-3 fatty acids or other mitochondrial metabolic enhancers in treating cardiovascular complications of chronic renal failure?